519 related articles for article (PubMed ID: 24928329)
1. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
Bartlett R; Stokes L; Sluyter R
Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
[TBL] [Abstract][Full Text] [Related]
3. P2X7 receptor antagonists: a patent review (2010-2015).
Park JH; Kim YC
Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
[TBL] [Abstract][Full Text] [Related]
4. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
[TBL] [Abstract][Full Text] [Related]
5. P2X7 Receptor as a Therapeutic Target.
De Marchi E; Orioli E; Dal Ben D; Adinolfi E
Adv Protein Chem Struct Biol; 2016; 104():39-79. PubMed ID: 27038372
[TBL] [Abstract][Full Text] [Related]
6. [Effect of P2X7 receptor on inflammatory diseases and its mechanism].
Xu H; Liang SD
Sheng Li Xue Bao; 2013 Apr; 65(2):244-52. PubMed ID: 23598883
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
Baudelet D; Lipka E; Millet R; Ghinet A
Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
[TBL] [Abstract][Full Text] [Related]
8. The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases.
Morandini AC; Savio LE; Coutinho-Silva R
Biomed J; 2014; 37(4):169-77. PubMed ID: 25116711
[TBL] [Abstract][Full Text] [Related]
9. The P2X7 Receptor.
Sluyter R
Adv Exp Med Biol; 2017; 1051():17-53. PubMed ID: 28676924
[TBL] [Abstract][Full Text] [Related]
10. The evolution of P2X7 antagonists with a focus on CNS indications.
Rech JC; Bhattacharya A; Letavic MA; Savall BM
Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
[TBL] [Abstract][Full Text] [Related]
11. Effects of dexamethasone on purinergic signaling in murine mast cells: Selective suppression of P2X7 receptor expression.
Yoshida K; Ito M; Hoshino Y; Matsuoka I
Biochem Biophys Res Commun; 2017 Dec; 493(4):1587-1593. PubMed ID: 28988113
[TBL] [Abstract][Full Text] [Related]
12. The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
Chen Z; He L; Li L; Chen L
Clin Chim Acta; 2018 Apr; 479():196-207. PubMed ID: 29366837
[TBL] [Abstract][Full Text] [Related]
13. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease.
Shokoples BG; Paradis P; Schiffrin EL
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):186-199. PubMed ID: 32998520
[TBL] [Abstract][Full Text] [Related]
14. Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism.
McInnes IB; Cruwys S; Bowers K; Braddock M
Clin Exp Rheumatol; 2014; 32(6):878-82. PubMed ID: 25288220
[TBL] [Abstract][Full Text] [Related]
15. Significance of P2X7 receptor variants to human health and disease.
Sluyter R; Stokes L
Recent Pat DNA Gene Seq; 2011 Apr; 5(1):41-54. PubMed ID: 21303345
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of P2Y2 and P2X7 purinergic receptors in the isolated rat heart mediates ischemia-reperfusion injury.
Granado M; Amor S; Montoya JJ; Monge L; Fernández N; García-Villalón ÁL
Vascul Pharmacol; 2015 Oct; 73():96-103. PubMed ID: 26070527
[TBL] [Abstract][Full Text] [Related]
17. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
18. Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.
Al-Aqtash R; Collier DM
Channels (Austin); 2024 Dec; 18(1):2355150. PubMed ID: 38762911
[TBL] [Abstract][Full Text] [Related]
19. P2X7 receptor: an emerging target in central nervous system diseases.
Sperlágh B; Illes P
Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
[TBL] [Abstract][Full Text] [Related]
20. Inflammasome activation in bovine monocytes by extracellular ATP does not require the purinergic receptor P2X7.
Hussen J; Düvel A; Koy M; Schuberth HJ
Dev Comp Immunol; 2012 Oct; 38(2):312-20. PubMed ID: 22728096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
